Compare THG & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THG | KRYS |
|---|---|---|
| Founded | 1852 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.6B |
| IPO Year | 1996 | 2017 |
| Metric | THG | KRYS |
|---|---|---|
| Price | $223.16 | $346.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $194.60 | ★ $297.60 |
| AVG Volume (30 Days) | 282.4K | ★ 508.3K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | 55.21 | ★ 128.00 |
| EPS | ★ 10.58 | 3.62 |
| Revenue | ★ $6,594,400,000.00 | $389,130,000.00 |
| Revenue This Year | $2.71 | $38.74 |
| Revenue Next Year | $4.43 | $32.53 |
| P/E Ratio | ★ $21.09 | $93.10 |
| Revenue Growth | 5.72 | ★ 33.94 |
| 52 Week Low | $166.54 | $143.09 |
| 52 Week High | $236.07 | $382.54 |
| Indicator | THG | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 54.09 |
| Support Level | $176.82 | $253.89 |
| Resistance Level | $225.29 | $382.33 |
| Average True Range (ATR) | 4.19 | 10.03 |
| MACD | -1.24 | 1.62 |
| Stochastic Oscillator | 39.22 | 98.36 |
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business through Hanover Insurance, Citizens and other THG subsidiaries. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.